{
    "organizations": [],
    "uuid": "8d1aed8d21710bc53c03a2482e9a676f9be1dbf0",
    "author": "",
    "url": "https://www.reuters.com/article/brief-prometic-announces-realignment-of/brief-prometic-announces-realignment-of-its-clinical-program-priorities-for-2018-idUSFWN1QA13F",
    "ord_in_thread": 0,
    "title": "BRIEF-Prometic Announces Realignment Of Its Clinical Program Priorities For 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Prometic Life Sciences Inc:\n* PROMETIC ANNOUNCES REALIGNMENT OF ITS CLINICAL PROGRAM PRIORITIES FOR 2018\n* PROMETIC LIFE SCIENCES - AS PART OF REALIGNMENT, CO TERMINATED PBI-4050 CLINICAL TRIAL IN CYSTIC FIBROSIS RELATED DIABETES\n* PROMETIC LIFE SCIENCES INC - AS PART OF REALIGNMENT, CO IS EVALUATING NEED TO CONTINUE OTHER ON-GOING CLINICAL PROGRAMS WITH PBI-4050\n* PROMETIC LIFE SCIENCES-EVALUATING CLINICAL DEVELOPMENT STRATEGY REGARDING FOLLOW-ON COMPOUNDS WHICH SHARE SAME UNIQUE MECHANISM OF ACTION WITH PBI-4050 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-21T01:22:00.000+02:00",
    "crawled": "2018-02-21T01:35:44.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "prometic",
        "life",
        "science",
        "inc",
        "prometic",
        "announces",
        "realignment",
        "clinical",
        "program",
        "priority",
        "prometic",
        "life",
        "science",
        "part",
        "realignment",
        "co",
        "terminated",
        "clinical",
        "trial",
        "cystic",
        "fibrosis",
        "related",
        "diabetes",
        "prometic",
        "life",
        "science",
        "inc",
        "part",
        "realignment",
        "co",
        "evaluating",
        "need",
        "continue",
        "clinical",
        "program",
        "prometic",
        "life",
        "clinical",
        "development",
        "strategy",
        "regarding",
        "compound",
        "share",
        "unique",
        "mechanism",
        "action",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}